Antibody drug conjugates for ablating hematopoietic stem cells

US12171839B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Anthony Boitano · Newton, US
• Matthew Burger · Belmont, US
• Susan E. Cellitti · San Diego, US
• Michael Cooke · Brookline, US
• Catrin Finner · Planegg, DE
• Bernhard Hubert Geierstanger · Solana Beach, US
• Yunho Jin · San Diego, US
• Si Tuen Lee-Hoeflich · Lexington, US
• HongNgoc Thi Pham · San Mateo, US
• Siew Ho Schleyer · Emeryville, US
• Kathrin Tissot · Schwanau, DE
• Tetsuo Uno · San Diego, US
• Ben Wen · Encinitas, US

Key dates

• Filing date: Jun 6, 2022
• Grant date: Dec 24, 2024
• Expiry date: Jun 6, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.